会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 102. 发明公开
    • Leukotriene antagonists, their production, and compositions containing them
    • Leukotrienantagonisten,deren Herstellung und diese enthaltende Zusammensetzungen。
    • EP0104885A1
    • 1984-04-04
    • EP83305588.2
    • 1983-09-21
    • MERCK FROSST CANADA INC.
    • Belanger, Patrice C.Fortin, RejeanGuindon, YvanRokach, JoshuaYoakim, Christiane
    • C07C149/40C07C147/14C07C147/107C07D317/14C07D233/78C07D207/404C07D303/02C07C59/90A61K31/19C07C59/64C07C51/347
    • C07D207/26C07C45/71C07C59/90C07C317/00C07C323/00C07D207/33C07D233/74C07D257/04C07D307/58C07D317/34C07C49/84
    • Compounds of the formulae:

      and their pharmaceutically acceptable (including acid- addition) salts, which are novel, are antagonists of leukotrienes of C 4 , D 4 and E 4 , the slow reacting substance of anaphylaxis. They can be made into pharmaceutical compositions by incorporating them in a pharmaceutical carrier.
      In the formulae, each R is H, OH, SH, C 1-8 alkyl, C 2-8 alkenyl, CF 3 , C 1-8 alkoxy, C 1-8 alkylthio, phenyl, phenyl having C 1-3 alkyl or halogen substitution, phen (C 2-4 alkyl), halogen, amino, N(R 4 ) 2 , COOR 4 or CH 2 OR 4 where R 4 is H or C 1-8 alkyl, formyl, CN, CF 3 S or NO 2 ;
      each R' is R 4 ; OR 4 ; COOR 4 ; N(R 4 ) 2 ; SR 4 ; CH 2 OR 4 orCHO; , or together R' and R' are 0, CH 2 or
      Y is oxyge, sulfur, sulfoxide, sulfone,
      = NR 12 , = N - CO - R 13 or - N - CN, where R 11 is C 1-4 alkyl, R 12 is H or C 1-4 atkyl and R 13 is C 1-4 alkyl or C 1-4 alkoxy;

      Y' is Y,
      each R 1 is hydrogen or C 1-3 alkyl; each m is an integer from 0 to 6;
      R 2 is
      where Z is O. S, CH 2 , H and OH, C 1-4 alkenyl, or = N - R 14 , where R 14 is OH, CN, COOH, halogen, formyl, C 1-8 acyl, C 1-8 alkyl, C 1-8 alkoxy, C 1-8 halogenated alkyl, phenyl, or phenyl having C 1-3 alkyl or C 1-3 alkoxy substitution; each R e is H or C 1-4 alkyl; each R 7 is H, OH or C 1-4 alkyl; each R 8 is H or C 1-4 alkyl and is absent when the two indicated carbons are triply bonded;
      R 5 is COOR 4 ; CH 2 OH; CHO; tetrazole; NHSO 2 R 14 ; CON-HSO 2 R 14 hydroxymethylketone; CN; CON(R 7 ) 2 ; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR 15 where R 15 is:
      where each s is independently 0-3, R 6 is as defined above and R 16 is

      (A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 N heteroatoms or one N and one S heteratom, each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
      (B) W-R 17 where W is O, S or NH and R 17 contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical or an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

      each of r and q is 0-20 but r + q does not exceed 20; and
      p is 0 or 1;
      R 3 is C 1-6 alkyl or C 3-8 alkenyl;
      R 9 is C 1-8 alkyl, C 1-8 alkoxy or (CH 2 ) r R 5 , where r and R s are as defined above: and
      R 10 is H, C 1-8 alkyl; R 4 CO- or R 4 OCH 2 , where R 4 is as defined above.

      The compounds are prepared by condensing together two compounds having appropriately substituted benzene rings, one of which contains a halogen atom in the chain containing Y and Y', which removes a hydrogen atom from the ring of the other compound.
    • 下列化合物:及其药学上可接受的(包括酸加成)盐,它们是C4,D4和E4的白三烯拮抗剂,其是过敏反应的缓慢反应物质。 它们可以通过将其并入药物载体中而制成药物组合物。 式中,R为H,OH,SH,C 1-6烷基,C 2-6烯基,CF 3,C 1-6烷氧基,C 1-6链炔基,苯基,具有C1-3烷基或卤素取代基的苯基,苯基(C2 -4烷基),卤素,氨基,N(R4)2,COOR4或CH2OR4,其中R4是H或C1-6烷基,甲酰基,CN,CF3S或NO2; 每个R 1是R 4; OR 4; COOR4; N(R 4)2; SR4; CH2OR4或CHO; 或R 1和R 2分别为O,CH 2或CH 2 Y,是氧,硫,亚砜,砜,= NR 11,= NR 12,= N-CO-R 13或-N-CN,其中R 11为C 1-4 烷基,R 12为H或C 1-4烷基,R 13为C 1-4烷基或C 1-4烷氧基; Y min为Y,-CH 2 - 或 - 每个R 1是氢或C 1-3烷基; 每个m是0至6的整数; 其中Z是O,S,CH2,H和OH,C1-4链烯基或= N-R14,其中R14是OH,CN,COOH,卤素,甲酰基,C1-6酰基,C1-6烷基, C 1-6烷氧基,C 1-6卤代烷基,苯基或具有C 1-3烷基或C 1-3烷氧基取代基的苯基; 每个R 6是H或C 1-4烷基; 每个R 7是H,OH或C 1-4烷基; 每个R 8为H或C 1-4烷基,当两个表示的碳原子键合时不存在; R5为COOR4; CH2OH; CHO; 四唑; NHSO2R14; CONHSO2R14羟甲基酮; CN; CON(R7)2; 含有酸性羟基的单环或双环杂环; 或COOR 15,其中R 15为:其中各s独立地为0-3,R 6如上所定义,R 16为(A)含有3至12个核碳原子和1或2个N杂原子的单环或双环杂环基,或 一个N和一个S杂原子,杂环基中的每个环由5或6个原子形成,或(B)W-R 17,其中W是O,S或NH,R 17含有最多21个碳原子,并且是(1)a 烃基或(2)环中含有不超过1个杂原子的酰基或有机酰基或单环羧酸; r和q各自为0-20,但r + q不超过20; p为0或1; R3是C1-6烷基或C3-6烯基; R 9是C 1-6烷基,C 1-6烷氧基或(CH 2)r R 5,其中r和R 5如上所定义; R 10为H,C 1-6烷基; R4CO-或R4OCH2,其中R4如上所定义。 通过将具有适当取代的苯边缘的两种化合物冷凝在一起制备化合物,其中一个在含有Y和Ymin的链中含有卤素原子,其从另一种化合物的环除去氢原子。